Literature DB >> 30614094

Establishment of a diabetic myocardial hypertrophy model in Mus musculus castaneus mouse.

Jie Zhang1, Hongmei Qiu1, Jiajun Huang1, Shumei Ding1, Bo Huang2, Qin Wu2, Qingsong Jiang1.   

Abstract

The aim of this study was to establish a robust model of diabetic myocardial hypertrophy in Mus musculus castaneus mice. Mice were fed a high-fat diet for four weeks and then given streptozotocin (STZ, 40 mg kg-1  d-1 for 5 days, intraperitoneally) and fasting blood glucose (FBG) levels were tested after seven days. Mice with FBG levels above 11.1 mmol/L were considered diabetic. Diabetic mice continued to have access to the high-fat diet until cardiac hypertrophy developed. FBG and body weight (BW) were measured weekly. Myocardial hypertrophy was confirmed by left ventricle (LV) hypertrophy index (LVHI), LV/BW, LV histopathological observation and atrial natriuretic factor (ANF) mRNA expression. Serum insulin and plasma haemoglobin A1c (HbA1c) levels, total cholesterol (TCH) and triglyceride (TG) were measured, and then an insulin resistance index (HOMA.IR) was calculated. The level of FBG in the model group remained above 11.1 mmol/L, and the BW showed significant weight loss, compared with the control group (P < 0.01). The high levels of HbA1c, HOME.IR, TCH and TG, and the low level of insulin suggested that glucose metabolism was not balanced with insulin resistance; meanwhile, higher TCH and TG showed that dyslipidaemia had also developed. After the diabetic mice were kept on the high-energy diet for another four  weeks, histopathological observation showed myocardial injuries, much more surface area and collagen fibres, higher LVHI and LV/BW, and elevated expression of ANF mRNA (P < 0.01), suggesting that myocardial hypertrophy had appeared in Mus musculus castaneus mice under the current experimental conditions. Thus a robust model of diabetic myocardial hypertrophy was established four  weeks after confirmation of diabetes, which was induced by feeding a high-fat diet for four weeks combined with a repeated low-dose STZ exposure, in Mus musculus castaneus mice.
© 2019 The Authors. International Journal of Experimental Pathology © 2019 International Journal of Experimental Pathology.

Entities:  

Keywords:  Mus musculus castaneus mice; animal model; diabetic cardiomyopathy; myocardial hypertrophy

Mesh:

Substances:

Year:  2019        PMID: 30614094      PMCID: PMC6384502          DOI: 10.1111/iep.12296

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  23 in total

1.  How viral infections enhance or prevent type 1 diabetes-from mouse to man.

Authors:  M von Herrath; C Filippi; K Coppieters
Journal:  J Med Virol       Date:  2011-09       Impact factor: 2.327

2.  Effects of icariside II ameliorates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by activating Akt/NOS/NF-κB signaling.

Authors:  Lu Yang; Chaosheng Peng; Jing Xia; Wenluo Zhang; Li Tian; Yuhong Tian; Xiaobin Yang; Yuean Cao
Journal:  Mol Med Rep       Date:  2017-12-22       Impact factor: 2.952

3.  Low-dose IGF-I has no selective advantage over insulin in regulating glucose metabolism in hyperglycemic depancreatized dogs.

Authors:  S J Fisher; Z Q Shi; H L Lickley; S Efendic; M Vranic; A Giacca
Journal:  J Endocrinol       Date:  2001-01       Impact factor: 4.286

4.  Treatment and risk factor analysis of hypoglycemia in diabetic rhesus monkeys.

Authors:  Sirong He; Younan Chen; Lingling Wei; Xi Jin; Li Zeng; Yan Ren; Jie Zhang; Li Wang; Hongxia Li; Yanrong Lu; Jingqiu Cheng
Journal:  Exp Biol Med (Maywood)       Date:  2011-02

5.  Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of Th1 cytokines correlates with beta-cell destructive insulitis and IDDM.

Authors:  A Rabinovitch; W Suarez-Pinzon; A El-Sheikh; O Sorensen; R F Power
Journal:  Diabetes       Date:  1996-06       Impact factor: 9.461

6.  Activation of nuclear β-catenin/c-Myc axis promotes oxidative stress injury in streptozotocin-induced diabetic cardiomyopathy.

Authors:  Peng Liu; Jianfang Su; Xixi Song; Shixiao Wang
Journal:  Biochem Biophys Res Commun       Date:  2017-10-06       Impact factor: 3.575

7.  The effects of dosage and the routes of administrations of streptozotocin and alloxan on induction rate of type1 diabetes mellitus and mortality rate in rats.

Authors:  Ataroalsadat Mostafavinia; Abdodlah Amini; Seyed Kamran Ghorishi; Ramin Pouriran; Mohammad Bayat
Journal:  Lab Anim Res       Date:  2016-09-30

8.  Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications.

Authors:  David André Barrière; Christophe Noll; Geneviève Roussy; Farah Lizotte; Anissa Kessai; Karyn Kirby; Karine Belleville; Nicolas Beaudet; Jean-Michel Longpré; André C Carpentier; Pedro Geraldes; Philippe Sarret
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

9.  Cardio-Protective Role of Gingerol along with Prominent Anti-Diabetic Cardiomyopathy Action in A Streptozotocin-Induced Diabetes Mellitus Rat Model.

Authors:  Li-Ya Yu; Wen-Lei Shi; Xin-GuiGuo Guo
Journal:  Cell J       Date:  2017-08-19       Impact factor: 2.479

10.  Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice.

Authors:  S Trembleau; G Penna; E Bosi; A Mortara; M K Gately; L Adorini
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  2 in total

1.  Establishment of a diabetic myocardial hypertrophy model in Mus musculus castaneus mouse.

Authors:  Jie Zhang; Hongmei Qiu; Jiajun Huang; Shumei Ding; Bo Huang; Qin Wu; Qingsong Jiang
Journal:  Int J Exp Pathol       Date:  2019-01-06       Impact factor: 1.925

2.  Metformin Shortens Prolonged QT Interval in Diabetic Mice by Inhibiting L-Type Calcium Current: A Possible Therapeutic Approach.

Authors:  Hui Wang; Cao Wang; Yuan Lu; Yan Yan; Dongjing Leng; Shanshan Tian; Dongjie Zheng; Zhiguo Wang; Yunlong Bai
Journal:  Front Pharmacol       Date:  2020-06-11       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.